Age appears to be a strong predictor of MS disease activity. With increasing age, relapse frequency and new inflammatory MRI lesions decline, and the accumulation of neurological disability accelerates. Also, there is a relative lack of efficacy of disease modifying therapies in people with progressive MS. Join Dr. Olaf Stuve to discuss disease progression in MS and options for people with a progressive disease course.
Age appears to be a strong predictor of MS disease activity. With increasing age, relapse frequency and new inflammatory MRI lesions decline, and the accumulation of neurological disability accelerates. Also, there is a relative lack of efficacy of disease modifying therapies in people with progressive MS. Join Dr. Olaf Stuve to discuss disease progression in MS and options for people with a progressive disease course.
read more
read less
@H. Shopping, Two recommended articles for more information are “Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial” (Ann Neurol. 2009 Oct;66(4):460-71) and “Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis” (N Engl J Med. 2017 Jan 19;376(3):209-220). You can find the full version of both manuscripts in PubMed.
@Rooster Caine Thank you! The National MS Society recently did a podcast for Veterans on anxiety and PTSD. The speaker was from the VA. You can view the podcast at https://www.youtube.com/watch?v=FBC7QnEU64U.
I'm interested in learning more about some studies that Dr. Stuve mentioned. The name was spoken quite quickly. It sounded like Dr. Viviana Vilikova but I can't find it in a quick search. Are there any links to the study and others mentioned here?